Skip to main content
OpenTrials

Clinical trial condition

Neuroectodermal Tumors

Explore clinical trials studying Neuroectodermal Tumors. Study availability and eligibility vary by location and protocol.

6,011 public trials 1,221 recruiting studies
Refine in advanced search Browse all conditions

Neuroectodermal Tumors trial results

Completed

Non Interventional Post Marketing Programme in Neuroendocrine Tumours

NCT00747786

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +3 more
Locations
  • University Hospital of Wales Cardiff, United Kingdom
  • Aintree University Hospital Liverpool, United Kingdom
  • Royal Free Hospital London, United Kingdom
  • St. Bartholomew's Hospital London, United Kingdom
View Trial Details
Completed

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain

NCT03220087

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +3 more
Locations
  • Hospital General Univ. de Elche Alicante, Spain
  • ICO Badalona Badalona, Spain
  • Hospital Clínico y Provincial de Barcelona Barcelona, Spain
  • Hospital de Bellvitge Barcelona, Spain
View all 28 locations
View Trial Details
Completed

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

NCT01614795

Conditions
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, +34 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
View all 76 locations
View Trial Details
Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

NCT01595009

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +3 more
Locations
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Chemnitz, Germany
  • Novartis Investigative Site Erlangen, Germany
View Trial Details

Related conditions